Correlation Between Defence Therapeutics and Marizyme
Can any of the company-specific risk be diversified away by investing in both Defence Therapeutics and Marizyme at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Defence Therapeutics and Marizyme into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Defence Therapeutics and Marizyme, you can compare the effects of market volatilities on Defence Therapeutics and Marizyme and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Defence Therapeutics with a short position of Marizyme. Check out your portfolio center. Please also check ongoing floating volatility patterns of Defence Therapeutics and Marizyme.
Diversification Opportunities for Defence Therapeutics and Marizyme
0.35 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Defence and Marizyme is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Defence Therapeutics and Marizyme in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Marizyme and Defence Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Defence Therapeutics are associated (or correlated) with Marizyme. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Marizyme has no effect on the direction of Defence Therapeutics i.e., Defence Therapeutics and Marizyme go up and down completely randomly.
Pair Corralation between Defence Therapeutics and Marizyme
Assuming the 90 days horizon Defence Therapeutics is expected to generate 0.02 times more return on investment than Marizyme. However, Defence Therapeutics is 43.86 times less risky than Marizyme. It trades about 0.21 of its potential returns per unit of risk. Marizyme is currently generating about -0.02 per unit of risk. If you would invest 40.00 in Defence Therapeutics on September 19, 2024 and sell it today you would earn a total of 1.00 from holding Defence Therapeutics or generate 2.5% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.45% |
| Values | Daily Returns |
Defence Therapeutics vs. Marizyme
Performance |
| Timeline |
| Defence Therapeutics |
| Marizyme |
Defence Therapeutics and Marizyme Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Defence Therapeutics and Marizyme
The main advantage of trading using opposite Defence Therapeutics and Marizyme positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Defence Therapeutics position performs unexpectedly, Marizyme can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marizyme will offset losses from the drop in Marizyme's long position.| Defence Therapeutics vs. Aileron Therapeutics | Defence Therapeutics vs. Enlivex Therapeutics | Defence Therapeutics vs. Living Cell Technologies | Defence Therapeutics vs. Multicell Techs |
| Marizyme vs. Deere Company | Marizyme vs. Caterpillar | Marizyme vs. Lion Electric Corp | Marizyme vs. Nikola Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |